Who’s paying for lunch? Here’s exactly how drug companies wine and dine our doctor

23rd Nov 2018, New Delhi

Source: The Conversation

In June 2015, 24 Australian cancer specialists flew to Chicago to attend a five-day conference. Drug giant Amgen funded the trip, including registration, transfers and wining and dining. It cost almost A$270,000.

In December 2013, in a teaching hospital in New South Wales, 11 pharmacists and pharmacy technicians attended a 45-minute presentation by a pharmaceutical representative from a company called Menarini. The presentation was accompanied by a Continue reading

Advertisements
Posted in Access to Medecines, Pharmaceutical Benefits Scheme | Leave a comment

The West is not the best

20th Nov 2018, New Delhi

Source: DNA

 

RCEP Summit

The cross-country intellectual property rights (IPRs) wars are back and this time it’s being fought in the East.

From last week’s RCEP conversations in Singapore, it seems like Japan and South Korea are pushing other Asian countries like India and China to accede to stricter IPR norms.

Public health activists are concerned about this resulting in raising prices of medicines, given that patent term extensions and stricter data exclusivity requirements could expand monopoly power of patent holders.

Infact, current World Bank chief economist, Pinelopi Goldberg and co-authors in a 2006 Continue reading

Posted in Regional Comprehensive Economic Partnership | Leave a comment

Switzerland should stop pushing for TRIPS-plus measures in trade agreement with Indonesia

20th Nov 2018, New Delhi

Source: Public Eye

Swiss and Norwegians civil society groups led by Public Eye and Third World Network addressed on September 11, 2018, their serious concerns in an open letter to their Minister of Trade over TRIPS-plus provisions being included in the Comprehensive Economic Partnership Agreement (CEPA), currently under negotiation between the European Free Trade Association (EFTA) and Indonesia. The reply from the Swiss government doesn’t address those concerns and makes some very problematic assertions. Public Eye therefore reiterates its call on Switzerland/EFTA to remove all TRIPS-plus provisions from the final CEPA with Indonesia.

Continue reading

Posted in TRIPS, TRIPS plus, TRIPS&IP rights | Leave a comment

To scale-up TB preventive therapy, we need to bundle tools & improve access

20th Nov 2018, New Delhi

Source: Microbiology

Shortage of tuberculin, expensive X-ray hardware, limited access to IGRAs, and lack of registration of rifapentine pose big barriers for high-burden countries to scale-up preventive therapy. It is time to convene all LTBI product manufacturers, negotiate a ‘bundled price’ & address supply chain problems.

Approximately 1.7 billion individuals are estimated to be latently infected with Mycobacterium tuberculosis globally. While the majority will not progress to TB disease, we can and must prevent TB disease in those who are newly infected and those at high risk of progression.

Thankfully, there are now shorter treatments that are highly effective, and we now have good, consolidated guidelines from WHO. In parallel, high-burden countries are starting to acknowledge the need to test and treat TB infection in high-risk populations (e.g. people living with HIV, child contacts).

The global TB community has ambitious targets for preventive therapy. The first-ever UN Continue reading

Posted in Access to Medecines, Tuberculosis (TB) | Leave a comment

PM Narendra Modi arrives in Singapore for RCEP Summit

15th Nov 2018, New Delhi

Source: LiveMint

Prime Minister Narendra Modi with the Indian diaspora in Singapora on Wednesday. Photo: Twitter/@NarendraModiSingapore: Prime Minister Narendra Modi arrived in Singapore on Wednesday for a two-day visit during which he will attend the East Asia Summit, an ASEAN-India informal meet, the Regional Comprehensive Economic Partnership (RCEP) summit and hold a meeting with US vice president Mike Pence.

Modi’s first engagement here would be to deliver the keynote address at the Singapore Fintech Summit, the Prime Minister’s Office (PMO) said in a tweet. “The Prime Minister Continue reading

Posted in FTA, Regional Comprehensive Economic Partnership | Leave a comment

Health activists raise concerns over IP provisions at RCEP

15th Nov 2018, New Delhi

Source: Times of India

MUMBAI: Public health activists and patient groups have raised serious concerns over intellectual property (IP) provisions in the ongoing negotiations of regional comprehensive economic partnership (RCEP), charging Japan and South Korea of pushing a TRIPS-plus regime which would expand and extend monopolies for pharma MNCs, and undermine generic competition. This, in effect, would impact generic competition that is critical for lowering medicines prices, and hence keep them unaffordable for millions of patients across the developing world.

By “resisting pressure” in the past, and safeguarding its generic industry, India —often referred as ‘a pharmacy of the developing world,’ has become a leading supplier of Continue reading

Posted in Access to Medecines, FTA, Regional Comprehensive Economic Partnership | Leave a comment

Narendra Modi’s RCEP dilemma

Other RCEP participants have been pushing India to sign on the dotted line to conclude the deal by the year-end. But it isn’t quite that easy for the Narendra Modi government

15th Nov 2018, New Delhi

Source: Live Mint

When he visited Japan late last month, Prime Minister Narendra Modi “reaffirmed the strategic importance of the early conclusion of the negotiations for…Regional Comprehensive Economic Partnership (RCEP) Agreement for realizing full benefits of a free and open Indo-Pacific region”.

But an early conclusion doesn’t seem to be on the cards as he heads to Singapore this week Continue reading

Posted in FTA, Regional Comprehensive Economic Partnership | Leave a comment